n.a. (SNT)

0.12
0.00 (0.00)
AMEX
Prev Close 0.12
Open 0.12
Day Low/High 0.12 / 0.12
52 Wk Low/High 0.11 / 0.32
Exchange AMEX
Div & Yield N.A. (N.A)
Emerging Biotech Companies Discuss What’s In The Pipeline At NYSSA Conference

Emerging Biotech Companies Discuss What’s In The Pipeline At NYSSA Conference

Insiders from some of the sector’s most innovative small- and micro-cap biotech companies will discuss their progress with trials and their plans to develop, research, and market important new drugs, diagnostics ...

Senesco Initiates Dosing In Phase 1b/2a Clinical Study Of SNS01-T

Senesco Initiates Dosing In Phase 1b/2a Clinical Study Of SNS01-T

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced the initiation of patient dosing in its Phase 1b/2a clinical study of SNS01-T at the Mayo Clinic in Rochester,...

Senesco Technologies Provides Corporate Update

Senesco Technologies Provides Corporate Update

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) provided an update on Company activities.

Senesco Technologies Receives Notice Of Non-Compliance From NYSE Amex

Senesco Technologies Receives Notice Of Non-Compliance From NYSE Amex

Senesco Technologies, Inc. (the “Company”) (NYSE Amex: SNT) has received a notice from the NYSE Amex LLC (the “NYSE Amex”) providing notification that the Company does not meet one of the NYSE...

Senesco Technologies To Present At BIO Investor Forum Conference

Senesco Technologies To Present At BIO Investor Forum Conference

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at the BIO Investor Forum conference on Tuesday, October 25 th.

Senesco Technologies Reports Fiscal Year 2011 Financial Results

Senesco Technologies Reports Fiscal Year 2011 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced financial results for the 12 months ended June 30, 2011 (“Fiscal 2011”).

Senesco To Present At 13th Annual Rodman & Renshaw Healthcare Conference

Senesco To Present At 13th Annual Rodman & Renshaw Healthcare Conference

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at the 13 th Annual Rodman & Renshaw Healthcare Conference being held at the...

Senesco Finalizes Agreement With Mayo Clinic To Study SNS01-T In Multiple Myeloma

Senesco Finalizes Agreement With Mayo Clinic To Study SNS01-T In Multiple Myeloma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced that it has finalized a clinical trial agreement with Mayo Clinic in Rochester, MN to study SNS01-T, the...

Senesco Technologies Selects Criterium To Manage Multiple Myeloma Study

Senesco Technologies Selects Criterium To Manage Multiple Myeloma Study

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced that it has contracted Criterium, Inc.

Senesco Technologies Told By FDA It May Proceed – SNS01-T IND Is Open

Senesco Technologies Told By FDA It May Proceed – SNS01-T IND Is Open

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced that the Company has been told by the U.

Senesco Technologies To Present At The 14th Annual Meeting Of American Society Of Gene And Cell Therapy

Senesco Technologies To Present At The 14th Annual Meeting Of American Society Of Gene And Cell Therapy

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that it will deliver a poster presentation at the 14 th Annual Meeting of the American Society of Gene &...

Senesco Technologies Reports Third Quarter Fiscal 2011 Financial Results

Senesco Technologies Reports Third Quarter Fiscal 2011 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced financial results for the third quarter ended March 31, 2011.

Senesco’s Lead Therapeutic Candidate SNS01-T Waiting For Update To Vendor’s Drug Master File

Senesco’s Lead Therapeutic Candidate SNS01-T Waiting For Update To Vendor’s Drug Master File

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT), announced today that the U.

Senesco Technologies To Present At The ROTH 23rd Annual OC Growth Stock Conference

Senesco Technologies To Present At The ROTH 23rd Annual OC Growth Stock Conference

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) announced today that the Company will be presenting at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15,...

Senesco Technologies Reports Second Quarter Fiscal 2011 Financial Results

Senesco Technologies Reports Second Quarter Fiscal 2011 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the second quarter ended December 31, 2010.

Senesco Technologies To Present At The 13th Annual BIO CEO & Investor Conference

Senesco Technologies To Present At The 13th Annual BIO CEO & Investor Conference

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that Leslie J.

Senesco Technologies Announces IND Filing With FDA For SNS01-T

Senesco Technologies Announces IND Filing With FDA For SNS01-T

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company has filed an Investigational New Drug (“IND”) application with the U.

Senesco Technologies To Present At American Association For Cancer Research’s Special Conference

Senesco Technologies To Present At American Association For Cancer Research’s Special Conference

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that it will deliver a poster presentation at the American Association for Cancer Research’s Special...

Senesco Technologies’ Lead Therapeutic Candidate SNS01-T Granted Orphan Drug Status From FDA For Treatment Of Multiple Myeloma

Senesco Technologies’ Lead Therapeutic Candidate SNS01-T Granted Orphan Drug Status From FDA For Treatment Of Multiple Myeloma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that the U.

Senesco Technologies To Present At The New York Society Of Security Analysts’ 14th Annual Biotech & Specialty Pharmaceuticals Industry Conference

Senesco Technologies To Present At The New York Society Of Security Analysts’ 14th Annual Biotech & Specialty Pharmaceuticals Industry Conference

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced that Leslie J.

Senesco Technologies Reports First Quarter Fiscal 2011 Financial Results

Senesco Technologies Reports First Quarter Fiscal 2011 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex:SNT) today reported financial results for the first quarter ended September 30, 2010 of fiscal year 2011.

Senesco Technologies Awarded Funding Under The U.S. Patient Protection And Affordable Care Act

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced it has been awarded $244,479 in immediately available funds from the U.

Senesco Technologies Regains NYSE Amex Listing Compliance

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company has received a letter from the NYSE Amex LLC (the Exchange) informing Senesco that it has now resolved matters...

Senesco Technologies Reports Fiscal Year 2010 Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) reported financial results for the 12 months ended June 30, 2010 (“Fiscal 2010”).

Senesco Technologies To Present At Fifth Annual JMP Securities Healthcare Conference

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company will be participating in the Fifth Annual JMP Securities Healthcare Conference being held at the Palace Hotel in...

Senesco Technologies To Present At Rodman & Renshaw 12th Annual Global Investment Conference

Senesco Technologies To Present At Rodman & Renshaw 12th Annual Global Investment Conference

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company will be participating in the Rodman & Renshaw 12 th Annual Global Investment Conference being held at the...

Senesco Names Biopharmaceutical Executive Dr. Leslie Browne As President And CEO

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that Leslie J.

Preclinical Data For Senesco’s SNS-01 To Be Presented At The American Society Of Gene And Cell Therapy Annual Meeting

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that preclinical data for the Company’s lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American...

Senesco Technologies Reports Fiscal Third Quarter Financial Results

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced financial results for the three and nine months ended March 31, 2010.

Senesco Technologies To Present At 6th Annual Rodman & Renshaw Global Healthcare Conference

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex:SNT) today announced that the Company will be presenting at the 6 th Annual Rodman & Renshaw Global Healthcare Conference being held at the ...